CIA
RCKT icon

Concurrent Investment Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Concurrent Investment Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,500
Closed -$6.13K – 1581
2025
Q2 		$6.13K Buy
+2,500
New +$12.7K ﹤0.01% 1402

Other funds holding RCKT

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Concurrent Investment Advisors's RCKT Position: Q2 2026 in Review

Concurrent Investment Advisors reduced its Rocket Pharmaceuticals (RCKT) stake by 6.9% in Q2 2026, selling an estimated $16.3K and leaving 65,717 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #1875.

Concurrent Investment Advisors first reported a position in RCKT in Q2 2025 and has held it in 5 quarters since. The position peaked at $253K in Q1 2026. 33 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Concurrent Investment Advisors held 65,717 shares of Rocket Pharmaceuticals worth $225K as of Q2 2026.
  • Concurrent Investment Advisors sold 4,908 Rocket Pharmaceuticals shares in Q2 2026, an estimated $16.3K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1875 holding.
  • Concurrent Investment Advisors first reported a position in Rocket Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Concurrent Investment Advisors's Rocket Pharmaceuticals position peaked at $253K in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.